Related Experiment Video

Updated: Jun 24, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells

Min Guan1, Lijun Zhu, George Somlo

  • 1Department of Clinical Molecular Pharmacology, Division of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA, 91010, USA.

Anticancer Research
|April 1, 2009
PubMed
Abstract

Insights

Fibroblast growth factor receptor 3 (FGFR3) expression correlates with bortezomib efficacy in multiple myeloma. Elevated FGFR3, particularly Y373C mutations, may indicate resistance to bortezomib treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Fibroblast growth factor receptor 3 (FGFR3) is deregulated in about 20% of multiple myeloma (MM) cases.
  • The role of FGFR3 expression in MM treatment response remains unclear.

Purpose of the Study:

  • To investigate the association between FGFR3 expression and the therapeutic efficacy of bortezomib in multiple myeloma.
  • To determine if specific FGFR3 mutations influence bortezomib response.

Main Methods:

  • Cell proliferation and apoptosis assays were conducted.
  • U266 cells with varying levels of FGFR3 expression (wild-type, Y373C mutant, K650E mutant) were utilized.
  • Western blotting was used to assess protein expression levels.

Main Results:

  • Bortezomib treatment reduced cell survival in a dose-dependent manner.
  • FGFR3 protein expression levels were also dose-dependent on bortezomib.
  • Bortezomib-induced apoptosis was correlated with FGFR3 expression.
  • Increased p-STAT3, Mcl-1, and VEGF expression suggested bortezomib resistance associated with Y373C mutation and wild-type FGFR3, potentially mediated by p-STAT3 signaling.

Conclusions:

  • FGFR3 expression, including wild-type and Y373C mutations, is linked to bortezomib resistance in multiple myeloma.
  • The p-STAT3 signaling pathway may play a role in mediating this resistance.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...